CD146 is a potential immunotarget for neuroblastoma

Area of Science:

• Oncology
• Molecular Biology
• Cancer Therapeutics

Background:

• Neuroblastoma is the most common pediatric extracranial solid tumor.
• High-risk or recurrent neuroblastoma has a poor prognosis despite current therapies.
• Novel therapeutic strategies are urgently needed for neuroblastoma treatment.

Purpose of the Study:

• To investigate the expression of CD146 (melanoma cell adhesion molecule) in neuroblastoma.
• To evaluate the anti-tumor effects of targeting CD146 in neuroblastoma cells.
• To explore CD146 as a potential therapeutic target for neuroblastoma.

Main Methods:

• Assessed CD146 expression in neuroblastoma cell lines and clinical samples.
• Utilized short hairpin RNA (shRNA) to knock down CD146 expression.
• Administered an anti-CD146 polyclonal antibody for in vitro and in vivo studies.
• Investigated apoptosis and signaling pathways (FAK, NF-κB).

Main Results:

• CD146 was expressed in neuroblastoma cell lines and primary tumors.
• CD146 knockdown or antibody treatment inhibited neuroblastoma cell growth in vitro.
• Anti-CD146 antibody treatment significantly reduced tumor growth in vivo.
• Inhibition of CD146 led to increased apoptosis via FAK and/or NF-κB pathways.

Conclusions:

• CD146 is expressed in neuroblastoma and serves as a potential therapeutic target.
• Targeting CD146 demonstrates significant anti-tumor activity against neuroblastoma.
• CD146-targeting therapies warrant further investigation for neuroblastoma treatment.